In clinical practice, a few studies have discovered serum markers that can early predict the development of T2DM with cognitive impairment, such as sFas, sFasL, and P-tau (Dove et al., 2021; Chi et al., 2022; Zheng et al., 2023). The gene discussed is FASLG; the disease is Cognitive impairment.